BioSpace News Archive

ASLAN Pharmaceuticals announced that it will host the third and final webinar in its series of Key Opinion Leader events on the emerging atopic dermatitis landscape and eblasakimab on Wednesday, June 22, 2022, at 10:00am ET.

Tiziana Life Sciences Ltd (NASDAQ: TLSA) (" Tiziana " or the " Company "), a clinical-stage biopharmaceutical company enabling breakthrough immunotherapies via novel routes of administration today announced that its Chief Executive Officer and Chief Scientific Officer, Kunwar Shailubhai, Ph.D., will present at the Biotechnology Innovation Organization (BIO) Annual Convention taking place at the San Diego Convention Center, Monday June 13 - Thursday, June 16, 2022.

Phase 2 clinical data on the efficacy of D-PLEX 100 in surgical site infection prevention in elective colorectal surgery will be presented during a poster presentation.

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its presence at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting to be held in Vancouver from June 11-14.

Medison Pharma announced today an exclusive multi-regional agreement with argenx to commercialize efgartigimod in 14 countries.

NT-I7 plus pembrolizumab showed anti-tumor activity in heavily pretreated patients for whom checkpoint inhibitors are usually ineffective.

Seven Presentations Will Include Unique Research on the New Biotrue ® Hydration Plus Multi-Purpose Solution and Biotrue ® Hydration Boost Lubricant Eye Drops.

Willow Biosciences Inc. announced today that Willow has incorporated the Onyx Genome Engineering Platform into its strain engineering workflows.

Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer.

Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer.